Strategic and Tactical Competitive Insights
Intelligence that drives winning strategies, from development through commercialization.
Intelligence that drives winning strategies, from development through commercialization.
We help biopharma teams uncover threats, seize opportunities, and make strategic decisions with confidence. Our recommendations are grounded in primary research, real-time conference intelligence, and proprietary analytical tools.
How We Work
- Primary intelligence: Rapid KOL, market and industry stakeholder interviews, payer and patient research through QuickAnswers and custom engagements
- Conference coverage: Before, during, and after major congresses (e.g. ASCO, ESMO, ASH, AHA, JPM) with previews, real-time tracking, and strategic debriefs
- Wargames & workshops: AI-powered, human-in-the-loop, competitive simulations through LucidWargames, plus traditional facilitated workshops
- Continuous monitoring: Competitive landscape tracking via proprietary tools, such as LucidScope and LucidSearch
We provide decision support across:
- Asset Clinical Development and Commercialization
- R&D and Pipeline Assets
- Market Access
- Pricing/Reimbursement
- Regulatory Needs
- Emerging Markets
- Biosimilars/Generics
- OTC Offerings
- Digital Health
Across the full product lifecycle:
- New Product Planning
- Brand Planning
- Mature Product Planning
Our research capabilities are bolstered by in-house experts and a network spanning:
- Oncology/Hematology (solid/liquid tumors etc.)
- Gene and Cell Therapy / Rare Diseases (muscular dystrophy, ophthalmology, hemophilia etc.)
- Inflammatory and Autoimmune Diseases (including rheumatology, dermatology, allergy, MS etc.)
- Neurological Disorders (including epilepsy, Alzheimer’s, schizophrenia, PD etc.)
- Respiratory Disorders (including asthma, COPD, IPF, PAH etc.)
- Cardiovascular Disorders / Diabetes (including stroke, lipid disorders etc.)
- Infectious Diseases / Vaccines (including HIV, HCV, flu, MRSA, RSV etc.)
- Pain (including chronic pain, cancer-associated pain etc.)
- Blood Disorders (e.g. hemophilia)
Build Intelligence That Compounds (Powered by NexusBrain)
Every engagement generates valuable insight: KOL perspectives, congress observations, wargame scenarios, competitive assumptions. Too often, this intelligence lives in static reports and forgotten slide decks.
LucidQuest engagements can be integrated with NexusBrain (nexusbrain.io), a platform that captures, structures, and activates employee-driven and expert-validated intelligence. Primary research findings, conference observations from your own teams, and wargame outputs become a searchable, cumulative asset, not one-off deliverables.
The result: every engagement makes your organization’s intelligence sharper, and gives your AI tools better inputs to work with.
Learn more at nexusbrain.io
Ready to build winning competitive strategies?
Let’s accelerate your success together. Contact us at info@lqventures.com.
March 13, 2026
Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal
March 12, 2026
Rare Disease Video Recap—March 12, 2026
March 12, 2026
Cardiovascular Video Recap—March 12, 2026
March 12, 2026
Cardiovascular Today—March 12, 2026
March 12, 2026
Rare Diseases Today—March 12, 2026
March 12, 2026
Lucid Diligence Brief: Agilent acquires Biocare Medical for $950 million
March 11, 2026
Neuroscience Today—March 11, 2026
March 11, 2026
Immunology Video Recap—March 11, 2026
March 11, 2026
Immunology Today—March 11, 2026
March 11, 2026
Lucid Diligence Brief: Eli Lilly $500 million South Korea biopharma pledge
March 10, 2026